Product Description
Famotidine is used to treat stomach ulcers (gastric and duodenal), erosive esophagitis (heartburn or acid indigestion), and gastroesophageal reflux disease (GERD). GERD is a condition where the acid in the stomach washes back up into the esophagus. (Sourced from: https://www.mayoclinic.org/drugs-supplements/famotidine-oral-route/description/drg-20072972)
Mechanisms of Action: H2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: COVID-19|Communicable Diseases|Duodenal Ulcer|Respiratory Tract Infections|Stomach Ulcer
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Master Protocol | P2 |
Active, not recruiting |
Respiratory Tract Infections|Communicable Diseases|COVID-19 |
2025-01-01 |
25% |
| IM026-1023 | P1 |
Recruiting |
Healthy Volunteers |
2024-03-24 |
28% |
| NCT04724720 | P2 |
Active, not recruiting |
COVID-19 |
2021-05-03 |
|
| CTR20131013 | P2 |
Recruiting |
Duodenal Ulcer |
None |